oral semaglutide novo nordisk oral glp-1 Nordisk's drug didn't work on Alzheimer's as hoped, but don't call it a failure FDA Approves Oral Semaglutide: First – Article » PBD

Chesnut, M

Canadian Access and Coverage Considerations Canadian patients face unique considerations when evaluating these medications

Sigalov, Y

33 In the DIANA-5 study (NCT05019989), patients in the upper tertile of adherence to the lifestyle intervention had lower rates of recurrence (HR, 0.59

Clinical evidence SELECT cardiovascular outcomes SELECT enrolled 17,604 adults aged 45 years with established atherosclerotic cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease) and BMI 27 kg/m, but without diabetes, randomizing them 1:1 to semaglutide 2.4 mg SC weekly (after titration) or placebo on top of standard CV therapies